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Abstract
Introduction: the relationship between smoking and sleep disturbance has been well documented. Smoking is a common risk 
factor for both obstructive sleep apnea (OSA) and cardiovascular diseases. The study aimed to: 1) evaluate the incidence of newly 
diagnosed OSA in patients presenting with symptoms suggestive of a sleep disorder, 2) assess the relation between smoking 
status and OSA severity; and 3) compare the prevalence of cardiovascular comorbidities in ever- and never smokers with newly 
diagnosed OSA.
Material and methods: a retrospective analysis of 5,353 patients suspected of OSA was performed. OSA was diagnosed on 
the basis of polysomnography. The influence of smoking status on indices of OSA severity was evaluated and the incidence of 
self-reported cardiovascular diseases and diabetes mellitus type 2 was analyzed in relation to smoking history. 
Results: OSA was diagnosed in 3,613 patients (67.5%); of these, 21.6% were ever-smokers. Smokers with OSA had a higher 
apnea-hypopnea index [AHI; 31 (18.4–53.29) vs 29 (18.3–47.7), p = 0.03], lower mean oxygenation during sleep [90.9 ± 4.0 vs
91 ± 3.7, p < 0.001] and a higher daytime sleepiness (Epworth Sleepiness Scale score 11.7 ± 5.5 vs 11.0 ± 5.5, p < 0.001). 
The most frequent comorbidity was hypertension, followed by obesity, diabetes mellitus type 2 and coronary artery disease, with 
a statistically higher incidence of hypertension in non-smokers (59.2 vs 64.7 %, p = 0.005). 
Conclusion: smoking is related with OSA severity and increased daytime sleepiness. Our study confirmed the elevated frequency 
of cardiovascular comorbidities in OSA patients in general but did not show an increased incidence of these comorbidities in 
smokers. 
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Introduction 
Obstructive sleep apnea (OSA) is the most 
common sleep disorder and is characterized by re-
current nocturnal airflow limitation in the upper 
airways, resulting in blood oxygenation decrease 
and subsequent arousals. According to the classic 
study by Young et al., OSA affects approximately 
4% of men and 2% of women aged 30–60 [1], 
however, in many later studies, a higher incidence 
of OSA was reported, and in some populations, 
it may reach as much as 23.4% in women and 
49.7% in men aged 40–85 [2].
The relationship between the diagnosis of 
OSA and smoking has been well documented. 
Smoking is associated with a decreased quality of 
sleep [3], daytime sleepiness and problems with 
falling and staying asleep [4]. Lin et al. hypothe-
sized that smoking contributes to OSA symp-
toms by inducing chronic inflammation of the 
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upper airways [5]. Smoking is also a recognized 
risk factor for cardiovascular diseases [6, 7]. 
This risk depends not only on the cumulative 
exposure to cigarettes expressed in pack-years 
but also on smoking habits, as smoking fewer 
cigarettes per day for a longer time showed to be 
more harmful than smoking more cigarettes for 
a shorter period [8]. 
Cardiovascular diseases are a frequent comor-
bidity in OSA [9]. It is estimated that 38–65% of 
patients with coronary artery disease and 12–55% 
of subjects with heart failure suffer from OSA [10]. 
Among patients with arterial hypertension, the 
prevalence of OSA ranges between 30% and as 
much as 83% [10]. Furthermore, several studies 
have shown that people with OSA are not only 
at a higher risk of cardiovascular morbidity, but 
also have a higher risk of cardiovascular-related 
mortality, particularly in the group of OSA pa-
tients with the severe form of the disease [11, 12]. 
In individuals with hypertension, OSA severity 
was found to be related with myocardial injury 
and this was independent from blood pressure 
control [13]. The pathogenesis of cardiovascular 
diseases in patients with OSA is multifactorial. 
The postulated causative factors include endo-
thelial dysfunction, oxidative stress, chronic in-
flammation, increased activity of the sympathetic 
nervous system, vascular stiffness and impaired 
glucose metabolism [14]. The contribution of each 
of these individual factors is difficult to determine 
because of the complex interaction between OSA 
and cardiovascular diseases. 
This study was aimed to analyze the relation 
between smoking status and daytime sleepiness 
and the incidence of cardiovascular comorbidities 
in newly diagnosed patients with OSA. The spe-
cific aims of the study were the following: 1) to 
evaluate the incidence of newly diagnosed OSA in 
patients presenting with symptoms suggestive of 
a sleep disorder, 2) to assess the relation between 
smoking status and OSA severity; and finally: 
3) to compare the prevalence of cardiovascular 
comorbidities in ever- and never smokers with 
newly diagnosed OSA. 
Material and methods
Study design 
This single-center retrospective observa-
tional study included patients referred to the 
institutional Sleep Laboratory due to symptoms 
suggestive of OSA. Patient evaluation included 
detailed medical history, basic anthropometric 
data and polysomnography to confirm or exclude 
OSA diagnosis. Cardiovascular diseases (arterial 
hypertension, history of myocardial infarction, 
coronary artery disease, chronic heart failure 
and, additionally, diabetes mellitus type 2) were 
recognized when the patients reported such pre-
vious diagnoses or if any of these conditions had 
been mentioned in the patient’s earlier medical 
reports. Clinical data and the parameters attained 
in polysomnography were analyzed in relation 
to smoking history and ever-smokers and non-
smokers were compared. 
According to our institutional policy, as this 
was a retrospective non-interventional study, the 
approval of the Review Board was not mandato-
ry. However, it should be emphasized that every 
patient managed in the Sleep Laboratory in our 
institution is asked to give signed consent for the 
potential use of his/her clinical data for research 
purposes, and only those who gave such consent 
were included in the analysis. 
Study population 
The participants of the study were recruited 
from subjects referred to the institutional Sleep 
Laboratory due to the suspicion of OSA between 
January 2007 and December 2017. The specific 
inclusion criteria were as follows: 1) age ≥ 18 
years and 2) newly diagnosed OSA in accor-
dance with the recommendations of the Polish 
Respiratory Society [15]. Patients who had been 
previously treated for snoring or OSA, as well as 
those with a previous history of central apnea syn-
dromes or restless leg syndrome were excluded 
from the study. 
OSA diagnosis 
Daytime somnolence was assessed with the 
use of the Epworth Sleepiness Scale (ESS) [16]. 
An ESS score greater than 10 points was consi-
dered as excessive daytime sleepiness [15]. All 
participants underwent nocturnal polysomno-
graphy (Alice 4 camera, RESPIRONICS, Mur-
rysville, Pennsylvania, USA and Embla S4000, 
Reykjavik, Iceland) to confirm or exclude the 
recognition of OSA. OSA diagnosis and seve-
rity were established in accordance with the 
recommendations of the American Academy 
of Sleep Medicine (AASM) and the Polish Re-
spiratory Society. The diagnostic criteria were 
as follows: apnea-hypopnea index (AHI) > 5/h 
coupled with typical symptoms or AHI > 15/h 
regardless of the presence of symptoms of OSA. 
The range of AHI values for mild, moderate and 
severe OSA were 5–15/h, 16–30/h and > 30/h, 
respectively [15, 16]. 
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Assessed for eligibility 
(suspicion of OSA) 
n = 5353
OSA confirmed in PSG 
n = 3613
OSA excluded in PSG 
n = 1740
Ever-smokers
n = 794
Non-smokers
n = 2819
Ever-smokers
n = 360
Non-smokers 
n = 1380
Figure 1. Flow chart of the participants of the study; OSA: obstructive sleep apnea; PSG: polysomnography
Statistical analysis
Normally distributed data were presented 
as mean with standard deviation. Variables with 
non-normal distribution were expressed as me-
dian and interquartile range (IQR). Correlations 
between variables were assessed using Spearman 
r coefficient. For comparison of continuous data 
between the two groups, Student t-test and 
Mann-Whitney test were applied. The analysis 
of covariance (ANCOVA) was used to determine 
effect of smoking status on sleepiness controlling 
for covariates. Discrete variables were expres-
sed as percentages and were compared using 
Chi-square test with Yates’s  correction, when 
applicable. All performed tests were 2-tailed 
and differences between the compared groups 
were recognized as statistically significant with 
p-value < 0.05. 
All calculations were done in R version 
3.4.0 — environment for statistical computing. 
Standard and “car” packages were used [17, 18]. 
Results
In the analyzed period, 5,353 subjects (3,556 
men and 1,797 women, mean age 57.3 ± 9.5 years) 
were referred and diagnosed in our department. 
The diagnosis of OSA was confirmed in 3,613 
(67.5%) patients, with the majority of cases 
(49.0%) being in the severe form. As expected, the 
mean ESS score was higher in patients with OSA 
when compared to the non-OSA group. There was 
a marked predominance of men in both groups, 
however, the proportion of men was significantly 
higher in patients with OSA. OSA subjects were 
older and had a higher body mass index (BMI). 
The number of ever-smokers and non-smokers in 
both groups was comparable (Fig. 1). 
The prevalence of arterial hypertension, my-
ocardial infarction and diabetes mellitus type 2 
was higher in patients with OSA when compared 
to the non-OSA group, while the prevalence of 
coronary artery disease and chronic heart failure 
did not differ significantly between the groups 
(Table 1).
OSA in smokers and in non-smokers
Ever-smokers comprised 22.0% of the analyzed 
patients with OSA, and the median number of pack– 
years in this group was 20 (15–30). There was no 
difference in the relative distribution of OSA severity 
between the two groups, but smoking patients with 
OSA had a significantly higher AHI, lower mean 
oxygen saturation and declared a higher daytime 
sleepiness than those who did not smoke, and this 
applied both to men and women (Tables 2, 3). 
One-way ANCOVA revealed that smoking sta-
tus did not have a significant effect on sleepiness 
after controlling for age, AHI, mean saturation 
during polysomnography both in men (F 2.352, 
p.0.05) and in women (F 0.552, p > 0.05). The 
number of pack-years was not correlated with AHI 
(r = –0.093, p > 0.05), ODI (r = –0.024, p > 0.05), 
SpO2mean (r = –0.035, p > 0.05) and SpO2min 
(r = 0.027, p > 0.05).
OSA comorbidities in relation to smoking 
status 
The most frequent comorbidity in the whole 
investigated group of patients with OSA was hy-
pertension, followed by obesity, diabetes mellitus 
type 2 and coronary artery disease. With the ex-
ception of hypertension, which was significantly 
more frequent in non-smoking OSA patients, the 
frequency of the analyzed comorbidities did not 
differ between the two groups (Table 3). 
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Table 1.  Clinical characteristics of the studied population and the comparison between patients with obstructive sleep 
apnea (OSA) and those in whom OSA was not confirmed (OSA and non-OSA groups, respectively) 
Parameter All subjects  
(n = 5353)
Subjects with OSA  
(n = 3613)
Non-OSA subjects  
(n = 1740)
p-value
Age [years] 57.3 ± 9.5 57.5 ± 9.4 56.9 ± 9.6  < 0.05
BMI [kg/m2] 30.7 ± 5.7 31.5 ± 5.9 29.2 ± 4.9  < 0.001
Obesity*, n (%) 2623 (49) 1973 (54.6) 650 (37.3)  < 0.001
Men, n (%) 3554 (66.4) 2597 (71.9) 957 (55.0)  < 0.001
Epworth Sleepiness Scale score 
(ESS)
10.1 ± 5.5 11.1 ± 5.5 7.8 ± 4.7  < 0.001
Ever-smokers, n (%) 1154 (21.6) 794 (22.0) 360 (20.6)  >0.05
AHI [n per hour] 18.7 (7.5–38.4) 29.3 (18.3–48.9) 4.7 (2.1–9.0)  < 0.001
ODI [n per hour] 11.0 (3.6–26.4) 18 (8.4–34.2) 3.1 (1.1–7.3)  < 0.001
SpO2 mean [%] 91.9 ± 3.5 91.4 ± 3.8 93 ± 2.6  < 0.001
SpO2 min [%] 82 (75–86) 79 (73–84) 86 (82–89)  < 0.001
OSA severity mild/moderate/ 
/severe (%)
– 16.1/34.9/49.0 – –
Hypertension, n (%) 3239 (60.5) 2293 (63.5) 946 (54.4)  < 0.001
Diabetes mellitus type 2, n (%) 792 (14.8) 567 (15.7) 225 (12.9)  < 0.01
Coronary artery disease, n (%) 920 (17.2) 637 (17.6) 285 (16.3)  >0.05
Myocardial infarction, n (%) 75 (1.4) 60 (1.7) 15 (0.9)  < 0.05
Chronic heart failure, n (%) 21 (0.4) 18 (0.5) 3 (0.2)  >0.05
BMI: body mass index; AHI: apnea-hypopnea index; ODI: oxygen desaturation index, SpO2 mean: mean oxygen saturation during polysomnography; SpO2 min: minimal 
oxygen saturation during polysomnography; COPD: chronic obstructive pulmonary disease
*BMI > 30 kg/m2
Table 2. Comparison between smokers and non-smokers with obstructive sleep apnea (OSA)
Parameter Ever-smokers with OSA
(n = 796)
Non-smokers with OSA
(n = 2817)
p-value
Age [years] 53.8 ± 8.0 58.6 ± 9.5  < 0.001
BMI [kg/m2 ] 31.5 ± 6.3 31.5 ± 5.8 > 0.05
Obesity*, n (%) 435 (54.6) 1538 (54.6) > 0.05
Men, n (%) 620 (77.9) 1977 (70.2)  < 0.001
Epworth Sleepiness Scale score 11.7 ± 5.5 11.0 ± 5.5  < 0.001
AHI [n per hour] 31 (18.4–53.2) 29 (18.3–47.7)  < 0.05
ODI [n per hour] 17.4 (8.0–37.0) 18.3 (8.5–33.5) >0.05
SpO2 mean [%] 90.9 ± 4.0 91.5 ± 3.7  < 0.001
SpO2 min [%] 79 (72–84) 80 (73–84) >0.05
OSA severity mild/moderate/severe (%) 15.3/32.9/51.8 16.4/35.4/48.2 >0.05
Hypertension, n (%) 471 (59.2) 1822 (64.7)  < 0.01
Diabetes mellitus type 2, n (%) 121 (15.2) 446 (15.8) > 0.05
Coronary artery disease, n (%) 127 (16.0) 510 (18.1) > 0.05
Myocardial infarction, n (%) 11 (1.4) 49 (1.7) > 0.05
Chronic heart failure, n (%) 3 (0.4) 15 (0.5) > 0.05
BMI: body mass index; AHI: apnea–hypopnea index; ODI: oxygen desaturation index; SpO2 mean: mean oxygen saturation during polysomnography; SpO2 min: minimal 
oxygen saturation during polysomnography; COPD: chronic obstructive pulmonary disease
*BMI > 30 kg/m2
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Table 3. Comparison of smokers and non-smokers in women and men with OSA
Parameter Women with OSA (n = 1016) p-value Men with OSA (n = 2597) p-value
Smokers  
(n = 176)
Non-smokers
(n = 840)
Smokers
(n = 620)
Non smokers
(n = 1977)
Age [years] 55.3 ± 7.5 61.2 ± 8.7  < 0.001 53.4 ± 8.1 57.4 ± 9.6  < 0.001
BMI [kg/m2] 30.8 ± 7.3 31.3 ± 6.7 > 0.05 31.7 ± 5.9 31.5 ± 5.6 > 0.05
Obesity*, 
n (%)
81 (46 %) 442 (53%) > 0.05 350 (56%) 1084 (55%) > 0.05
Epworth Sleepiness 
Scale score
11.5±5.5 10.4±5.5  < 0.05 11.8 ± 5.5 11.2 ± 5.4  < 0.05
AHI 
[n per hour]
24.8 (5–123.9) 23.8 (5–118.7) > 0.05 33.0 (5–118.3) 31.2 (5–134.5) > 0.05
ODI 
[n per hour]
14.8 (0–107.5) 15.1 (0–102.7) > 0.05 22.9 (0–110.8) 20.0 (0–187.8) > 0.05
SpO2 mean [%] 91.2 ± 4.2 91.8 ± 3.5  < 0.05 90.8 ± 3,9 91.4 ± 3.8  < 0.01
SpO2 min [%] 78.8 (50–93) 80 (50–94) > 0.05 79 (49–94) 79 (41–96) > 0.05
OSA severity mild/ 
/moderate/severe [%]
16.7/30.1/43.2 21.2/33.6/38.8  < 0.05 12.1/33.7/54.2 14.3/33.5/52.2 > 0.05
BMI: body mass index; AHI: apnea-hypopnea index; ODI: oxygen desaturation index; SpO2 mean: mean oxygen saturation during polysomnography; SpO2 min: minimal 
oxygen saturation during polysomnography
*BMI > 30 kg/m2
Discussion
Our study showed that OSA may be con-
firmed in approximately two thirds of patients 
presenting with symptoms of a sleep disorder and 
that the majority of persons with newly diagnosed 
OSA suffer from the severe form of the disease. 
We found that smoking had an impact on OSA 
severity and daytime symptoms. In the analyzed 
group, smokers had a significantly higher AHI, 
lower mean oxygen saturation during sleep and 
declared a higher daytime sleepiness than those 
who did not smoke. Arterial hypertension was 
the most frequent comorbidity in both groups 
and, interestingly, it was more frequent in non-
smokers than in smokers. To our knowledge, this 
is the first study to show the impact of smoking 
status on the course of OSA and the incidence of 
cardiovascular comorbidities in a Polish cohort 
of OSA patients.
The detrimental effect of smoking on sleep 
has been well documented. Smokers have greater 
difficulty with falling asleep and maintaining 
sleep continuity, and report more sleepiness 
during the day [4]. This may be related not only 
to the stimulant properties of nicotine per se but, 
even more importantly, to the degree of nicotine 
addiction [19]. On the other hand, inhalation of 
cigarette smoke contents causes irritation of the 
throat and subsequent local edema of the mucosa 
of the upper airways, which may be one of the 
contributing factors to upper airway obstruction 
and an increased risk of OSA. Smokers are several 
times more likely to experience respiratory sleep 
disorders than non-smokers [20], and have been 
reported to increase daytime sleepiness [21]. Our 
results are in line with these observations. We 
have shown that smokers with OSA have a si-
gnificantly higher ESS score than non-smokers. 
Smoking patients with OSA also had a remarkably 
higher AHI compared to non-smokers, despite 
a younger age and a comparable BMI. However, 
increased daytime sleepiness in smokers found 
in our cohort was not confirmed in the analysis 
performed after controlling for age, AHI and BMI. 
In view of the above, we may assume that a higher 
ESS score in smokers with OSA may rather be 
attributed to the increased probability of respira-
tory disorders in response to smoking than to the 
direct impact of nicotine on sleepiness during day.
Arterial hypertension is one of the most 
frequent comorbidities in OSA. Hypertension is 
diagnosed in 30% to even 83% of patients with 
OSA, while 30–35% of hypertensive patients suf-
fer from OSA [10, 22–24]. These observations were 
confirmed in our study. Hypertension was the 
most frequent self-reported cardiovascular comor-
bidity and was present in the vast majority of the 
investigated patients. Interestingly, it was more 
frequently reported by non-smokers than by smo-
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kers. One of the possible explanations for this fin-
ding may be related to the younger age of smokers 
in the investigated cohort. According to the guide-
lines of the Polish Society of Hypertension and 
the European Society of Cardiology (ESC) on the 
diagnosis and management of hypertension [25], 
age over 55 years has a more predictive value in 
the diagnosis of hypertension than smoking and 
the occurrence of OSA. 
Coronary artery disease was the second 
most frequent cardiovascular comorbidity in 
our patients. This is in line with the results of 
previous studies which showed that OSA is an 
independent factor of coronary heart disease and 
myocardial infarction [26, 27]. Although we did 
not show significant differences in the inciden-
ce of coronary artery disease in ever-smokers 
and non-smokers with OSA, the proportion of 
patients with a history of myocardial infarction 
was significantly higher in subjects with confir-
med OSA when compared to persons in whom 
OSA was excluded. Our results also confirmed 
the increased likelihood of diabetes mellitus type 
2 in individuals with OSA [28]. In the investi-
gated group, self-reported diagnosis of diabetes 
was significantly more frequent in patients with 
OSA compared to those in whom OSA was not 
confirmed. We did not, however, find differences 
in the incidence of diabetes in smoking and non-
smoking OSA patients.  
The major limitation of our study is that the 
diagnosis of cardiovascular diseases and diabetes 
mellitus type 2 was based on patient self-reported 
data. Considering the retrospective nature of the 
study, this could not have been avoided. Howe-
ver, we made full effort to verify these data in the 
patients’ available earlier medical documentation. 
On the other hand, epidemiological research 
based on self–reported patient data is frequently 
encountered in the literature [29, 30]. 
Conclusions 
To summarize, we showed that OSA may be 
diagnosed in the majority of patients presenting 
with symptoms suggestive of sleep disorders and 
referred for polysomnography. Almost half of ne-
wly diagnosed subjects with OSA suffer from the 
severe form of the disease. Our study confirmed 
the increased frequency of hypertension, diabetes 
mellitus type 2 and past myocardial infarction 
in patients with OSA. Smoking was related with 
OSA severity and more pronounced abnormalities 
during sleep and increased daytime sleepiness. 
Our findings on the impact of smoking status on 
the course of OSA and OSA cardiovascular comor-
bidities need to be confirmed in large population 
prospective studies. 
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